Tyson saw an overall positive second quarter performance for fiscal year 2025 despite subpar performances across the Springdale, Ark. company’s multi-protein portfolio.
During their earnings …
This item is available in full to subscribers.
To continue reading, you will need to either log in to your subscriber account, below, or purchase a new subscription.
Please log in to continue |